MPN (Myeloproliferative Neoplasms) Clinical Trial
Official title:
A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)
Verified date | May 2024 |
Source | Incyte Corporation |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to evaluate the efficacy and safety of pemigatinib (INCB054828) in subjects with myeloid/lymphoid neoplasms with fibroblast growth factor receptor (FGFR) 1 rearrangement.
Status | Active, not recruiting |
Enrollment | 47 |
Est. completion date | July 31, 2024 |
Est. primary completion date | July 31, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Documented lymphoid or myeloid neoplasm with 8p11 rearrangement known to lead to FGFR1 activation, based on standard diagnostic cytogenetic evaluation performed locally, before signing informed consent for this study. - Eligible subjects must: - Have relapsed after stem cell transplantation or after other disease modifying therapy, OR - Not be current candidates for stem cell transplantation or other disease modifying therapies. - Note: All relapsed/refractory subjects must have evidence of either cytogenetic or hematological disease and have no evidence of residual toxicity (eg, graft-versus-host disease requiring treatment). - Life expectancy = 12 weeks. - Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2. Exclusion Criteria: - Prior receipt of a selective FGFR inhibitor. - History and/or current evidence of ectopic mineralization/calcification, including but not limited to soft tissue, kidneys, intestine, myocardia, or lung, except calcified lymph nodes and asymptomatic arterial or cartilage/tendon calcifications. - Current evidence of corneal disorder/keratopathy, including but not limited to bullous/band keratopathy, corneal abrasion, inflammation/ulceration, and keratoconjunctivitis, as confirmed by ophthalmologic examination. - Use of any potent cytochrome P450 3A4 inhibitors or inducers within 14 days or 5 half-lives (whichever is shorter) before the first dose of study drug. |
Country | Name | City | State |
---|---|---|---|
Austria | Ordensklinikum Krankenhaus Der Barmherzigen Schwestern Linz | Linz | |
Austria | Iii Med. Abteilung For Hematologie and Onkologie Hanuscfhkrankenhaus | Wien | |
Austria | Medical University of Vienna | Wien | |
Belgium | Universitair Ziekenhuis (Uz) Leuven | Leuven | |
Canada | Princess Margaret Cancer Center | Toronto | Ontario |
France | Centre Leon Berard | Lyon | |
France | Chu de Nice - Hospital L Archet | Nice Cedex 3 | |
France | Hospital Saint Louis | Paris Cedex 10 | |
France | Universitaire Du Cancer de Toulouse Institut Claudius Regaud Iuct-Oncopole | Toulouse Cedex 9 | |
Germany | University Medical Center Rwth Aachen | Aachen | |
Germany | Universitatsklinikum Halle (Saale) | Halle | |
Germany | Universitatsklinikum Jena | Jena | |
Germany | Universitatsklinikum Leipzig | Leipzig | |
Germany | University Hospital Mannheim | Mannheim | |
Germany | Johannes Wesling Klinikum Minden | Minden | |
Italy | Ospedale Papa Giovanni Xxiii | Bergamo | |
Italy | Azienda Ospedaliero-Universitaria Careggi (Aouc) | Florence | |
Japan | Kindai University Hospital | Osaka | |
Japan | Ntt Medical Center Tokyo | Tokyo | |
Spain | Hospital Clinico Universitario de Valencia | Valencia | |
Switzerland | Inselspital - Universitaetsspital Bern | Bern | |
Switzerland | Universitatsspital Zurich | Zurich | |
United Kingdom | Guys and St Thomas Nhs Foundation Trust | London | |
United Kingdom | Oxford University Hospitals Nhs Foundation Trust | Oxford | |
United States | Emory University - Winship Cancer Institute | Atlanta | Georgia |
United States | City of Hope National Medical Center | Duarte | California |
United States | Md Anderson Cancer Center | Houston | Texas |
United States | Franciscan St. Francis Health | Indianapolis | Indiana |
United States | Weill Cornell Medical Centers | New York | New York |
United States | Mayo Clinic Arizona | Phoenix | Arizona |
United States | Washington University School of Medicine | Saint Louis | Missouri |
United States | University of Utah | Salt Lake City | Utah |
United States | Stanford Cancer Institute | Stanford | California |
Lead Sponsor | Collaborator |
---|---|
Incyte Corporation |
United States, Austria, Belgium, Canada, France, Germany, Italy, Japan, Spain, Switzerland, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The proportion of participants who achieve Complete Response (CR) based on response criteria for myeloid/lymphoid neoplasms with FGFR1 rearrangement | : Assessed at protocol-defined timepoints through end of study, up to approximately 24 months. | ||
Secondary | The proportion of subjects who achieve response, defined as a best response of CR or PR, as determined by investigator assessment according to the response criteria | Assessed at protocol-defined timepoints through end of study, up to approximately 24 months. | ||
Secondary | The proportion of subjects who achieve a complete cytogenetic response (CCyR) as assessed by local analysis and investigator evaluation | Assessed at protocol-defined timepoints through end of study, up to approximately 24 months. | ||
Secondary | The proportion of subjects who achieve a partial cytogenetic response (PCyR) as assessed by local analysis and investigator evaluation | Assessed at protocol-defined timepoints through end of study, up to approximately 24 months. | ||
Secondary | Duration of CR, defined as the time from first assessment of CR to the earlier of disease progression or death due to any cause | Assessed at protocol-defined timepoints through end of study, up to approximately 24 months. | ||
Secondary | Duration of response, defined as the time from first assessment of CR or PR to the earlier of disease progression or death due to any cause | Assessed at protocol-defined timepoints through end of study, up to approximately 24 months. | ||
Secondary | Progression-free survival (PFS) | PFS is defined as the time from the first date of taking study drug until the date of disease progression, as measured by response criteria for myeloid/lymphoid neoplasms with FGFR1 rearrangement, or until death due to any cause, whichever is earlier. | From the date of first study drug dose until the date of disease progression or until death due to any cause, whichever is earlier, assessed up to approximately 24 months. | |
Secondary | Overall survival | Overall survival is defined as the time from the first day of taking study drug until death due to any cause. Subjects without death observed at the time of the analysis will be censored at last date known to be alive. | From date of first study drug dose until death due to any cause, assessed up to approximately 24 months. | |
Secondary | Safety and tolerability as assessed by frequency, duration, and severity of adverse events | A treatment-emergent AE was defined as an event occurring after exposure to at least 1 dose of study drug. A treatment-related AE was defined as an event with a definite, probable, or possible causality to study medication. A serious AE is an event resulting in death, hospitalization, persistent or significant disability/incapacity, or is life threatening, a congenital anomaly/birth defect or requires medical or surgical intervention to prevent 1 of the outcomes above. The intensity of an AE was graded according to the National Cancer Institute common terminology criteria for adverse events (NCI-CTCAE) version 4.03: Grade 1 (Mild); Grade 2 (Moderate); Grade 3 (Severe); Grade 4 (life-threatening). | From baseline through 30-35 days after end of treatment, up to 7 months per individual subject |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03123588 -
Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)
|
Phase 2 | |
Completed |
NCT01348490 -
Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF)
|
Phase 2 | |
Completed |
NCT02252159 -
Prospective Observational Study Of Patients With Polycythemia Vera In US Clinical Practices (REVEAL)
|
||
Completed |
NCT01633372 -
An Open Label Study of Itacitinib Administered Orally in Patients With Myelofibrosis
|
Phase 2 | |
Completed |
NCT03144687 -
A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis
|
Phase 2 | |
Terminated |
NCT02718300 -
A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis
|
Phase 2 | |
Completed |
NCT02953704 -
Myelofibrosis and Essential Thrombocythemia Observational Study (MOST)
|
||
Completed |
NCT00952289 -
COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial
|
Phase 3 |